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Abstract
Quantitative analysis and mathematical models are useful tools in informing strategies to control or eliminate
disease. Currently, there is an urgent need to develop these tools to inform policy to achieve the 2020 goals for
neglected tropical diseases (NTDs). In this paper we give an overview of a collection of novel model-based analyses
which aim to address key questions on the dynamics of transmission and control of nine NTDs: Chagas disease,
visceral leishmaniasis, human African trypanosomiasis, leprosy, soil-transmitted helminths, schistosomiasis, lymphatic
filariasis, onchocerciasis and trachoma. Several common themes resonate throughout these analyses, including: the
importance of epidemiological setting on the success of interventions; targeting groups who are at highest risk of
infection or re-infection; and reaching populations who are not accessing interventions and may act as a reservoir
for infection,. The results also highlight the challenge of maintaining elimination ‘as a public health problem’ when
true elimination is not reached. The models elucidate the factors that may be contributing most to persistence of
disease and discuss the requirements for eventually achieving true elimination, if that is possible. Overall this
collection presents new analyses to inform current control initiatives. These papers form a base from which further
development of the models and more rigorous validation against a variety of datasets can help to give more
detailed advice. At the moment, the models’ predictions are being considered as the world prepares for a final
push towards control or elimination of neglected tropical diseases by 2020.
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Background
Neglected tropical diseases (NTDs) continue to create sig-
nificant levels of suffering and morbidity throughout the
tropical world. They affect over a billion people and accom-
pany HIV/AIDS, tuberculosis and malaria as the classic
‘diseases of poverty’ [1]. Considerable evidence suggests
that NTDs place major constraints on economic develop-
ment in most tropical countries [2]. The potential for large-
scale improvements in health equity by tackling these dis-
eases has been recognised in recent years by large-scale in-
vestment in controlling them. In January 2012, the World
Health Organization (WHO), laid out a roadmap for con-
trolling the burden of morbidity of neglected tropical dis-
eases [3]. This included goals for achieving control, local
elimination “as a public health problem”, or reduction in
disease burden to low levels by 2020. The London Declar-
ation on NTDs, signed in 2012, demonstrated the support
of the pharmaceutical industry, governments and non-
governmental agencies for the achievement of these goals
for ten diseases. Of these, one, Guinea worm, was targeted
for eradication. The remaining nine, lymphatic filariasis,
leprosy, human African trypanosomiasis, blinding trach-
oma, schistosomiasis, soil-transmitted helminthiasis, Cha-
gas disease, visceral leishmaniasis, and onchocerciasis
(Table 1) were targeted for control or “elimination as a pub-
lic health problem.”. Elimination as a public health problem
is defined differently for each disease, with individual dis-
ease goals set in accordance with the epidemiology of each
disease. Elimination as a public health problem as defined
by WHO does not necessarily require a break in transmis-
sion, rather a dramatic cut in disease incidence or
prevalence.
In the wake of the London Declaration a need has been
identified for epidemiological modelling to aid control
policy design and evaluation. Although the epidemio-
logical modelling of NTDs has a long history [4, 5], it has
been limited by both a lack of interest from funders and
limited epidemiological data on which to base the models.
In order to address this need, an international team of epi-
demiological modellers were brought together to form the
NTD Modelling Consortium. Members of the consortium
were asked to provide quantitative analyses to support the
NTD control efforts by
 validating current strategies,
 suggesting more impactful strategies,
 evaluating new tools as they arise from on-going
studies,
 providing guidance on what the ‘end game’, beyond
the 2020 goals, might look like.
Alongside this core project, the methods and models
developed by members of the consortium have the po-
tential to
 help countries understand whether they are on-track
to WHO goals and, if not, how long and what strat-
egies are needed to get there
 give countries guidance on when and how to best
check on progress
 provide guidance on certification of elimination
There would also be opportunities for extending NTD
models to include cost effectiveness and provide tools
for policy at a local level, depending on the quality of
the models and available data.
Importantly, for each of the diseases in this core re-
search (Table 1), the research team includes two or three
modelling groups per disease, to provide scientific ro-
bustness through investigating the same questions using
a variety of approaches, mirroring other modelling con-
sortia. The NTD Modelling Consortium is unusual
amongst existing modelling consortia because it crosses
a number of epidemiologically distinct infections, with
different types of etiological agents and modes of trans-
mission (Table 1). This diversity of diseases studied and
the range of research groups and approaches allows the
consortium to exploit similarities between diseases, such
as vector-borne dynamics or the impact of mass drug
administration (MDA), broadening the scientific base
from which the analyses are motivated. In addition the
research teams can work together to address common
problems such as clarity on definitions and sharing good
quality data. The group are also discussing different
methodologies and techniques for model validation, test-
ing and comparison.
The first analyses of these nine diseases by this re-
search team has been presented as a collection in Para-
sites and Vectors (http://www.parasitesandvectors.com/
series/ntdmodels2015) The analyses range from develop-
ing completely new models of diseases for which the epi-
demiology is still highly uncertain to bringing together
models with a long history in order to achieve consensus
on best strategies to achieve the 2020 goals. This paper
reviews these results with the aims of
– Introducing the collection to non-modellers
– Introducing the collection to modellers from related
fields
– Highlighting the key new policy insights
– Providing an overview across papers in the same
disease
– Providing an overview across diseases
The main part of this paper takes the reader through
the analyses disease by disease, starting with diseases
that are being treated through preventive chemotherapy
(PCT) (lymphatic filariasis, onchocerciasis, schistosomia-
sis, soil transmitted helminthiasis and trachoma)
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Table 1 Summary of the nine neglected tropical diseases studied in these papers, where elimination refers to elimination as a public health problem. Data sources: WHO
Name Transmission Global picture Interventions WHO target for 2020
Preventive chemotherapy (PCT) diseases, controlled by mass drug administration (MDA) programmes
Lymphatic filariasis (elephantiasis) Worm transmitted by mosquito Tropical and subtropical countries in Africa,
Asia, the Western Pacific, the Caribbean and
South America
Annual/biannual MDA (ivermectin,
albendazole and DEC), vector control
through insecticide-treated
bed nets or spraying
Global elimination
Onchocerciasis (river blindness) Worm transmitted by black fly Primarily occurs in tropical sub-Saharan
Africa (99 % of cases)
MDA (ivermectin) and vector control Country elimination
Schistosomiasis (bilharzia) Intestinal worm, water-borne
transmission with snail intermediate
host
Affect at least 240 million people worldwide.
Most commonly found in Africa, as well as
Asia and South-America
MDA (praziquantel) to school-age
children and high-risk adults, along
with WASH and possible snail
control
Regional and country
elimination
Soil-transmitted helminthiasis (roundworm,
whipworm, hookworm)
Intestinal worms transmitted via soil
contaminated with fecal matter
Over 1 billion people affected, particularly
in sub-Saharan Africa, India and Southeast
Asian countries
MDA (albendazole, mebendazole)
treatment of school-aged children.
Treatment of pre-school aged
children and women of childbearing
age is also recommended.
75 % coverage with
(bi)annual PCT
Blinding trachoma Bacterial infection transmitted by flies,
fingers and fomites.
84 million active cases globally. MDA (azithromycin) and surgery,
along with improved hygiene
Global elimination
Intensified disease management (IDM) diseases, controlled by increased diagnosis and management of cases
Chagas disease Protozoan transmitted by triatomines
(kissing bugs)
8 million infected in the Americas, 10,000
deaths per year.
Spraying with indoor residual insecticides,
housing improvements.
Regional elimination
HAT (sleeping sickness), Gambian form Protozoan transmitted by tsetse fly <4000 new cases in 2014 Treatment, active/mass screening and
vector control with tsetse targets.
Global elimination
Leprosy Bacterium with unclear mode of
transmission: contact or droplet likely
200,000 new diagnoses per year, >80 %
from India, Brazil and Indonesia
Early diagnosis and treatment Global elimination
Visceral leishmaniasis (kala-azar) in the Indian
sub-continent
Protozoan transmitted by sand fly 200,000–400,000 cases annually, 80 % in
Indian sub-continent.
Indoor residual spraying of insecticides,
insecticide-treated bed nets, active case
detection, rapid diagnosis and treatment
Regional elimination
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followed by the intensified disease management (IDM)
diseases (Chagas disease, the Gambian form of human
African trypanosomiasis, leprosy and visceral leishman-
iasis in the Indian sub-continent). These disease-specific
sections are followed by a discussion of general lessons
learned and next steps.
Preventive chemotherapy diseases
Preventive chemotherapy and transmission control
(PCT) is the main strategy for control of onchocerciasis,
lymphatic filariasis, schistosomiasis, soil-transmitted hel-
minthiasis and trachoma. The strategy involves regular
provision of preventive treatment (in the form of mass
drug administration (MDA) campaigns) to entire popu-
lations or targeted risk groups (e.g., schoolchildren). This
strategy reduces disease progression in treated individ-
uals and prevents transmission of infection to others.
Mass drug administration (MDA) programmes are rap-
idly expanding, although important questions remain.
For example, will the planned MDA programmes be suf-
ficient to achieve elimination in all epidemiological
settings? To what extent is successful elimination jeopar-
dized by low coverage and systematic non-adherence?
When, and on the basis of what criteria, can MDA be
safely interrupted [6]? Several of the modelling analyses
highlight the importance of groups who systematically,
or semi-systematically do not access MDA programs in
sustaining transmission. This potential for undermining
program success is particularly acute if groups of the
population who are most at risk through their behav-
iours (e.g., those who most frequently go to the river)
are also those who are most difficult to access through
an MDA campaign. The results support previous ana-
lyses that increased coverage, across different age
groups, or through general coverage, may be more im-
portant than frequency of treatment.
Lymphatic filariasis
Background
Lymphatic filariasis (LF) is caused by a group of
mosquito-borne filarial nematodes (Wuchereria bancrofti
(responsible for 90 % of cases), Brugia malayi or Brugia
timori) and can lead to chronic morbidity, such as
lymphedema, which is associated with pain, severe dis-
ability and resulting social stigmatisation [7–9]. About
1.2 billion people are at risk of LF in tropical and
subtropical countries in Africa, Asia, the Western
Pacific, the Caribbean and South America. The Global
Programme to Eliminate Lymphatic Filariasis (GPELF)
was launched in 2000, aiming to eliminate the disease as
a public health problem by 2020 by mass drug administra-
tion (MDA). In areas co-endemic with onchocerciasis, the
combination of drugs used in MDA is ivermectin (IVM)
and albendazole (ALB), whereas diethylcarbamazine
(DEC) and ALB are used in other endemic regions. The
current MDA strategy is to have yearly treatment at 65 %
coverage of the total population for at least 5 years,
followed by regular transmission assessments to identify
whether transmission has been broken. Morbidity man-
agement will accompany initiation of MDA programmes.
A number of countries have reached the targets of
stopping MDA and interrupting transmission, while
others have scaled up their treatment programmes and
are getting close to these targets, by reducing the risk of
infection for hundreds of millions of people [10]. How-
ever, there are still large numbers of affected popula-
tions, who are predominantly in sub-Saharan Africa, and
unlikely to receive the minimum 5 rounds of treatment
by 2020. In such areas, adjusted strategies may be
needed to accelerate elimination.
Modelling approaches
Three distinct models have been used to evaluate the
2020 goals in a number of key settings [11–13]. All
models capture heterogeneity in individuals’ exposure,
whilst there exist differences in assumed acquired im-
munity and filarial worm biology. The model by Irvine
et al. is an individual-based microsimulation. Model pre-
dictions were tested by fitting to the age-profile of infec-
tion in a survey prior to (Kenya) [14] and during an
intervention (Sri Lanka) [15] and predicting forward the
simulated microfilariae (mf) intensity distribution and
prevalence in subsequent years was compared and found
to be in good agreement to the data, but there were dis-
crepancies in ICT prevalence.
Jambulingam et al. used the established individual-
based, stochastic microsimulation model, LYMFASIM,
taking into account variability in immunity, transmission
potential and individual efficacy of MDA. The model
was fitted to age-specific, longitudinal data describing
the impact of integrated vector management on the in-
tensity of Wuchereria bancrofti infection in Pondicherry,
India [16].
Singh et al. [12] used a deterministic and age-
structured model of genus-specific LF transmission. The
model was calibrated using 22 pre-control settings from
Africa, South East Asia and Papua New Guinea. Fitting
was performed in a Bayesian melding framework to mf
age-prevalence in a pre-control setting.
Policy implications
Irvine et al. identify a number of key areas that are im-
portant to address with regards to an elimination
programme (Fig. 1a) [11]. Over a five-year timeline,
twice-yearly annual MDA at 65 % coverage was found to
be the most effective of all strategies considered. How-
ever, if twice-yearly MDA is not feasible, then an MDA
programme combined with vector control (VC) can also
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have a similarly high probability of success in all settings.
Annual MDA at 80 % coverage with no VC was found
to be only effective in low and medium settings (less
than 15 % mf prevalence) and annual MDA at 65 %
coverage was found to be only effective for lower en-
demic settings (less than 10 % mf prevalence). A number
of systematic adherence issues were found impact the
success of a programme such as individuals who are not
accessing the intervention also having higher risk of in-
fection; use of long lasting insecticidal nets (LLINs) be-
ing correlated with adherence to MDA for an individual;
and systematic compliance to MDA.
The model of Singh et al. indicates heterogeneity in
local transmission and extinction dynamics vary greatly
between settings (Fig. 1c) [12]. They showed that time-
lines to parasite elimination in response to the current
MDA and various proposed MDA strategies with vector
control also varied significantly between the study sites.
Assessment of annual bite rates without the presence of
vector control highlighted that very low prevalence is re-
quired to achieve true elimination because the subse-
quent probability of recrudescence is very high (between
69 and 100 %). Including VC, however, markedly reduces
the duration of interventions required to achieve elimin-
ation as well as decreasing the risk of recrudescence.
Jambulingam et al. use their model to investigate the
required duration of MDA to achieve elimination and to
assess how low the microfilaraemia and antigenaemia
prevalence must be to ensure elimination (Fig. 1b) [13].
The required number of treatment rounds for achieving
elimination was found to depend strongly on local trans-
mission conditions (reflected in baseline endemicity) and
achieved coverage. For instance, in low endemic settings
as few as 2 rounds might be sufficient if coverage is as
high as 80 %, while annual MDA may have to continue
for >10 years in high endemic areas if coverage is as low
as 50 %. The study also shows that the critical thresholds
used as endpoints for MDA, will be dependent on local
transmission conditions: in low-transmission settings
(low baseline endemicity) more residual infection may
remain than in high-transmission settings (high baseline
endemicity), because the relatively low biting rate in the
former prevents resurgence of infection.
Although different modelling approaches were used,
all models agree that timelines to LF elimination will de-
pend on the epidemiological conditions and achieved
coverage. These findings have important implications for
on-going elimination programmes that should be taken
into account in monitoring and evaluation. Transmission
assessment surveys should ideally be targeted at the sites
with the highest transmission intensity and lowest cover-
age: once elimination is achieved in these settings, it
should also be achieved in other settings where condi-
tions are more favourable for elimination.
Knowledge gaps and next steps
All three LF models have been fitted against mf preva-
lence data stratified by age. The use of mf and circulat-
ing filarial antigen (CFA) intensity measurements, where
such studies are available, would greatly enhance the fit
of the models to provide further insight into key under-
lying assumptions on exposure and immunity heterogen-
eity. A more direct comparison of the models for
particular settings would further establish the systematic
uncertainty between the models.
All three models need to be quantified and validated
against disease prevalence by incorporating knowledge
on disease dynamics and progression. This can help with
Fig. 1 Schematic of LF results. The results include: a) highlighting that heterogeneity in human exposure and intervention greatly alters time to
elimination by Irvine et al. [11]; b) a description of the association between antigenaemia and the presence of adult worms by Jambulinga et al.
[13]; and c) a Bayesian fitting methodology of a deterministic model including information on model inputs and outputs by Singh et al. [12]
Hollingsworth et al. Parasites & Vectors  (2015) 8:630 Page 5 of 28
setting new targets to reach the goal of LF elimination
as a public health problem and identify aspects that need
to be addressed to achieve this target. Models have to be
made user friendly with minimum inputs/outputs for ap-
plication in decision making and evaluation by
programme managers [17].
Onchocerciasis
Background
Human onchocerciasis is a disease caused by the filarial
nematode Onchocerca volvulus and transmitted by black-
fly vectors. Chronic infection can lead to skin disease, vis-
ual impairment and eventually blindness. It occurs
primarily in tropical sub-Saharan Africa but some foci also
exist in Yemen and Latin America. In recent decades, the
disease burden of onchocerciasis has been greatly reduced
by the Onchocerciasis Control Programme in West Africa
(OCP, 1974–2002), the African Programme for Onchocer-
ciasis Control (APOC, 1995–2015) and the Onchocercia-
sis Elimination Program for the Americas (OEPA, 1991-
present).
In the Americas, OEPA has successfully interrupted
transmission in most foci through 6- or 3-monthly mass
drug administration (MDA) of ivermectin [18–23]. Annual
or biannual ivermectin distribution has also eliminated on-
chocerciasis from several African foci [24, 25], although
elsewhere transmission is on going despite prolonged MDA
[26, 27]. In view of this evidence, the World Health
Organization (WHO) set ambitious targets for the elimin-
ation of onchocerciasis, which is to be achieved by 2015 in
the Americas and Yemen, by 2020 in selected African
countries, and by 2025 in 80 % of African countries [3, 28].
Modelling approaches
The individual-based microsimulation model, ONCHO-
SIM [29, 30] and the population-based deterministic
model EPIONCHO [31–33] have been developed
independently at Erasmus MC and Imperial College
London respectively.
A comparative modelling study is presented which ex-
plores the level of agreement between EPIONCHO and
ONCHOSIM in estimates of the required durations to
eliminate onchocerciasis. After harmonization of key in-
put assumptions, predictions were made for a range of
epidemiological settings (from mesoendemic to very
highly hyperendemic or holoendemic) and program-
matic (annual or biannual MDA at variable levels of
population coverage) characteristics.
Simulation endpoints were defined by two criteria: (1)
the duration of MDA required to reduce the mf preva-
lence below a threshold of 1.4 % (this is the provisional
operational threshold for treatment interruption
followed by surveillance (pOTTIS); and (2) the duration
of MDA required to drive the parasite to local elimin-
ation. This was determined by reaching the transmission
breakpoint in EPIONCHO and by a high (99 %) prob-
ability of stochastic fadeout in ONCHOSIM.
Policy implications
Both EPIONCHO and ONCHOSIM indicate that elim-
ination of onchocerciasis is feasible in mesoendemic set-
tings by annual MDA with ivermectin alone (Fig. 2). The
models’ predictions regarding the feasibility of elimin-
ation in settings with higher endemicity are more diver-
gent, however, with ONCHOSIM being more optimistic
than EPIONCHO. Both models agree that neither an-
nual nor bi-annual MDA will achieve elimination in
holo-endemic areas within a reasonable timeframe.
Therefore, in highly endemic settings alternative inter-
vention strategies should be considered.
More work is needed to validate the mf prevalence
threshold used as endpoint for MDA. Results from the
ONCHOSIM simulations indicate that, the 1.4 % thresh-
old was too low for lower endemicity settings, resulting
Fig. 2 Schematic of onchocerciasis results. The results include a comparison of a stochastic individual-based model (ONCHOSIM) and a deterministic
population-based model (EPIONCHO) and an investigation into the impact of systematic non-adherence in different endemicity settings by Stolk et al. [71]
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in unnecessary long continuation of MDA. The opposite
is true at higher endemicity settings; the time required
to reach the pOTTIS is shorter than the time required
to drive the parasite population to elimination. In prac-
tice, the decision to stop is made for entire areas, with
varying endemicity levels at baseline. The critical thresh-
old should be set low enough to ensure elimination in
the sites with highest transmission.
Knowledge gaps and next steps
Differences between EPIONCHO and ONCHOSIM in
the projected infection dynamics and required durations
to reach elimination will be further investigated to fully
understand the strengths and weakness of the two con-
trasting modelling approaches. Ultimately a process of
comparison, validation and refinement-followed by
finescale locale projections will help to reach consensus
on optimising intervention strategies to reach the global
health communities’ elimination objectives across Africa.
In order to perform these analyses, the researchers will
require access to similar datasets from long-term pro-
grammes. Through testing both model predictions
against these data, there can be increased confidence in
the predictions on how altered strategies can be used to
increase the probability of elimination.
Schistosomiasis
Background
Schistosomiasis, or bilharzia, is caused by the adult
worms and eggs of trematode flatworms of the genus
Schistosoma. The adult worms live in the blood vessels
where the females release eggs which are then passed
out of the body in urine or faeces. In freshwater these
eggs then infect snails, which subsequently release lar-
vae which pass into the skin during contact with water.
Eggs released in the body cause inflammation and scar-
ring of internal organs, leading to negative develop-
mental outcomes for children and adult pathology.
Highest prevalence is seen in children, who are targeted
for school-based deworming, which aims to control
morbidity. At-risk adults are also often targeted, how-
ever, the target of eliminating transmission may require
additional interventions, including water sanitation and
hygiene (WASH) as well as snail control.
Current WHO guidelines define broad prevalence
bands to indicate how school-age treatment should
proceed. Models can be used to investigate the impact of
this approach and update the guidelines to give them a
stronger scientific underpinning. However, it is expected
that current WHO control recommendations will need
to be substantially revised based on the WHA shift to-
ward 2020 elimination goals. The findings of present
modelling efforts, and the use of further ad hoc model-
based projections for different treatment scenarios, will
be able to inform the development of the next gener-
ation of more evidence-based WHO policy recommen-
dations for schistosomiasis control.
Modelling approaches
Modelling has been used to address many of the oper-
ational questions around frequency and needed coverage
of schistosomiasis treatment, but until now, rarely been
used to directly assess and predict the impact of PCT-
MDA control programmes.
The basic aims were to fit two existing models to
available detailed data for each parasite species, and to
determine the likely long-term impact of current select-
ive or MDA control programs to identify optimum anti-
helminthic treatment schedules to control schistosome
infection. The models sought to define these schedules
for low, medium and high transmission settings.
Two modelling approaches are proposed in the
current issue: one of them employs mean worm burden
formulation for age-structured populations [34], another
one is based on stratified worm burden setup. Both
modelling approaches incorporate the essential features
of in-host biology, such as worm mating and density-
dependent fecundity. The principal difference between
models lies in their underlying assumptions: the hypoth-
esized “negative binomial” worm burden distribution
[35], and the assumption-free “dynamic” worm strata
(with prescribed patterns of egg release) [36].
Anderson et al. [35] reconstructed the global trend in
MDA coverage from the mean of national coverage
data across endemic countries. This trend was then ex-
tended to estimate the likelihood of reaching the 2020
coverage target. These treatment estimates were then
used to project changes in average worm burdens up to
and beyond 2020.
Gurarie et al. [34] based their analysis on earlier cali-
brated models of Kenyan communities, and newer data
sets from the SCORE study in Mozambique. The short
term analysis assessed prevalence reduction under
SCORE regimens through the year 2020. The long term
analysis explored feasibility of specific target reduction
over 30-year period under different control scenarios.
Policy implications
Long-term control predictions of two model types did
differ in several respects. Specifically, the key ingredients
of this model, as employed in its analysis and simula-
tions, follow MDA impact on basic reproduction num-
ber, R0, and whether transmission breakpoints (resulting
from the underlying assumptions on worm distribution)
can be reached. Anderson et al. thus predict that persist-
ent long term MDA control can bring about elimination
of Schistosoma mansoni transmission (Fig. 3b), but this
was not the case for Gurarie et al. (Fig. 3a). The
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stratified worm burden systems in the model of Gurarie
et al. suggest that breakpoints may not exist or they
could be too low to be practically relevant (see [34]). An
important implication of control analysis by Gurarie et
al. is that MDA alone may not bring about elimination,
or sustained low-level infection, even under moderate-
to-low transmission intensity. Any successful end-game
strategy will require additional interventions, including
snail control, environmental and behavioral modifica-
tions related to exposure, sanitation, possibly with the
aid of vaccines.
Anderson et al. predict that the current trend in MDA
coverage, extrapolated to 2020, will have a major impact
on Schistosoma mansoni burdens overall, with reduc-
tions of around 85 % by 2020 and elimination within the
following decade in low transmission settings. Sensitivity
analysis suggests that some coverage of adults is essen-
tial to achieve elimination but little is to be gained in
transmission blocking by treating young children (pre-
school aged children). However, higher levels of adult
coverage show diminishing returns in terms of
effectiveness.
Of note, the two groups’ models agreed regarding the
need to achieve high levels of treatment coverage with
more frequent drug delivery (at least annual) for best ef-
fect, particularly in high transmission settings. The on-
going research will elucidate some of these issues,
including the value of mixed interventions, and help to
further develop optimal control strategies.
Knowledge gaps and next steps
Results from validation against re-infection data suggest
that other mechanisms are necessary to accurately re-
produce the age profile of infection after treatment. A
key difficulty is being able to resolve the influence of
age-dependent force of infection and immune response
mechanisms. Considerable inroads into the under-
standing of this complex area have already been made
[37, 38]. Combining these approaches with high quality
re-infection data should allow the contributions of dif-
ferent mechanisms to be more thoroughly teased out.
However, an essential component will be the availability
of high-quality longitudinal re-infection data, ideally at
the individual level, which is proving difficult to obtain.
The interpretation of raw data is hampered by issues
with current diagnostic techniques. Models of helminth
transmission are based around representations of worm
numbers within hosts, but the connection between
worm burdens and the output of egg-counting diagnos-
tic techniques, such as Kato-Katz, are not well charac-
terised, although it is known that sensitivities can be
quite low. Antigen and antibody based techniques prom-
ise more sensitive techniques, but lose the quantitative
Fig. 3 Schematic of schistosomiasis results. The results include: a) an assessment of the potential success of MDA in different scenarios using a
deterministic modelling framework by Gurarie et al. [36]; and b) an investigation into the feasibility of elimination using an age-structured
deterministic model by Anderson et al. [35]
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nature of the egg counts and will require careful calibra-
tion of the models [39].
The schistosomiasis researchers will continue to study
the impact of school-based and community based inter-
ventions on both S. mansoni and S. haematobium
through more detailed analysis of epidemiological stud-
ies, addressing the urgent need for these models to be
tested against multiple settings. They will also consider
the effect of WASH and snail control, where such data
are available. The aim will be to provide guidance on
which areas will need which interventions for control
and elimination.
Soil-transmitted helminthiasis
Background
Globally, over 1 billion people are infected with soil-
transmitted helminths (STH). The three major STH spe-
cies targeted for control are Ascaris lumbricoides
(roundworm) and Trichuris trichiura (whipworm), both
of which tend to exhibit highest prevalence and intensity
amongst children, and hookworm (Necator americanus
and Ancyclostoma), which tends to have highest preva-
lence and intensity amongst adults.
In recognition of the STH disease burden, the WHO
has set the target of implementing annual or semi-
annual MDA for pre-school- (preSAC) and school-aged
children (SAC) and women of childbearing age (WCBA)
in endemic areas with an overall coverage of at least
75 % by 2020. The associated parasitological goal is to
achieve <1 % prevalence of moderate-to-heavy intensity
infection in these target populations (and thus prevent
most morbidity). However, given that current programs
mostly target preSAC and SAC, the feasibility of control-
ling STH by 2020 with current strategies can be ques-
tioned, in particular for hookworm, which is most
abundantly present in adults.
The WHO goals and treatment guidelines do not dif-
ferentiate among the individual species that make up the
STH group, but categorise the treatment approach pri-
marily in terms of overall STH prevalence. In terms of
life-cycle and natural history within the host, this is a
reasonable assumption, although behaviour outside the
host differs but it ignores the significant quantitative dif-
ferences between species. Additionally, the guidelines
only consider a narrow range of responses to STH
prevalence (no treatment, annual or biannual treatment).
This is motivated by a desire to directly and cost-
effectively reduce morbidity in children, who are a key
risk group. However, it ignores the possible long-term
benefits of an approach that could reduce the contribu-
tions of the whole community to transmission, thereby
leading to transmission break and cessation of annual or
bi-annual treatment altogether.
The three species within STH have significant differ-
ences in age-intensity profiles, worm fecundity, and re-
sponse to treatment. The qualitative range profiles
indicate different distributions of worm burdens as well
as different forces of infection by age for the three spe-
cies. Further differences between species are indicated
by large differences in worm burden and the characteris-
tics of worm fecundity between species, as indicated by
worm expulsion studies. A further key difference in the
context of chemotherapeutic control strategies is the re-
sponse of the three species to treatment with the stand-
ard anthelminthic drugs, albendazole and mebendazole:
While these drugs are highly effective against Ascaris
and, to some extent, hookworm, efficacy against Tri-
churis is much lower, which could have an effect on the
choice of control strategy.
Modelling approaches
In this collection there are two models addressing con-
trol and elimination of the different soil-transmitted hel-
minths. Coffeng et al. presented WORMSIM, an
individual-based model for control by 2020 [40]. With
WORMSIM, the researchers synthesised relevant avail-
able information on hookworm biology, and capture het-
erogeneities in transmission and MDA participation.
The model predictions were compared to longitudinal
parasitological data in WCBA from Vietnam spanning
five years, collected pre-control and during PC. For vary-
ing levels of pre-control endemicity, the researchers pre-
dicted the impact of currently recommended MDA
strategies, as well as the impact of more intense strat-
egies (higher frequency and coverage of MDA), health
education and improved access to WASH, and system-
atic non-participation of individuals in MDA programs.
The approach of Truscott et al. was to use a determin-
istic age-structured model to describe the dynamics of
the parasites within the host population and the impact
of increasing levels of MDA coverage [41]. Stochastic in-
dividual based models were also constructed by Truscott
et al. but the average predictions were identical to the
deterministic model and hence the main focus in their
paper is on the deterministic outcomes. The same basic
model structure is employed for each of the STH spe-
cies, reflecting the very similar life-cycles of the three
species, but the parameterization in each case is based
on species-specific data taken from baseline age profiles
and expulsion studies. As a result, the dynamics of the
model in response to MDA is quite different for each
species. The accuracy of the model in describing the
evolution of worm burden under MDA was tested for
Ascaris against longitudinal baseline and reinfection
data. Model results are in broad agreement with the
data, with some discrepancies in individual age groups.
To drive the changes in worm burden up to and beyond
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2020, a long-term trend in MDA coverage was con-
structed to drive control and, potentially, elimination of
parasites. The trend was based on WHO records of aver-
age national coverage in SAC and pre-SAC in endemic
countries, interpolated forward in time to meet the pro-
posed 2020 goals or 75 % in SAC and pre-SAC. The data
suggests that current trends in MDA coverage are ap-
proximately in line with reaching the stated goals by
2020. Both models employed in this study are amenable
to the implementation of multiple forms of MDA, tar-
geting multiple helminth species using different drugs.
Detailed sensitivity analyses for parameter uncertainty
were performed as were validation studies using reinfec-
tion data post chemotherapy using parameter estimates
derived independently form the reinfection data.
Policy implications
The predictions by WORMSIM [40] confirm that to
achieve control of hookworm morbidity, women of
childbearing age have to be targeted with PC (Fig. 4b).
Furthermore, Coffeng et al. conclude that to achieve
control in highly endemic areas, the drug albendazole
should be preferred over mebendazole, and possibly add-
itional interventions such as health education and im-
proved access to WASH are needed (Fig. 4a). They also
illustrate how systematic non-participation to PC under-
mines programme effectiveness, even during high-
frequency PC.
Results from Truscott et al. [41] show that the impact
of the recent and planned increases in MDA coverage
will depend strongly on species. For Ascaris, worm bur-
den across the host population is reduced by 70 % by
2020, leading to elimination within the following decade
if coverage levels are maintained. The reduced efficacy
of albendazole against Trichuris mitigates the effect of
treatment against the species, achieving only a 44 % re-
duction in worm burden with no possibility of elimin-
ation with continued target levels of coverage. For
hookworm, the MDA is even less effective, due to the
bulk of worm burden (>70 %) being in adults who are
outside the treatment regime.
The implications are that the treatment response to
STH needs to be tuned to reflect the dominant species
in a given area. Where that species is Trichuris or hook-
worm, approaches beyond treatment of SAC may need
to be considered, particularly where transmission is high.
For hookworm, some degree of treatment of adults will
be necessary to significantly reduce burden or achieve
elimination. For Trichuris, a higher efficacy drug or
more frequent treatment could potentially be highly ef-
fective at reducing worm burden.
Knowledge gaps and next steps
As for schistosomiasis (above), the predictions of the im-
pact of age-based deworming programmes depend on
the assumptions of the contribution of different age
groups to transmission and of acquisition of infection
through a shared exposure to the ‘infective pool’. They
also highlight the challenges of interpreting Kato Katz,
although, unlike schistosomiasis, historic studies of the
relationship between egg output and adult worm burden
make the problem slightly less acute.
Next steps for these groups are to extend their model
validation to more species and multiple settings, and to
Fig. 4 Schematic of STH results. The schematic includes results from: a) a deterministic transmission model by Truscott et al. applied to Ascaris,
Trichuris and hookworm [41]; and b) a stochastic, individual based model of hookworm transmission by Coffeng et al. [40]
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do a more systematic model comparison of their predic-
tions to quantitative guidance on thresholds for different
treatment coverage.
Trachoma
Background
Trachoma remains the world’s leading cause of infec-
tious blindness [42]. Repeated ocular infection with the
bacterium Chlamydia trachomatis leads to episodes of
conjunctival inflammation. With repeated infection this
inflammation can progress to scarring. The resultant
scarring leads to the in-turning of eyelashes, known as
trachomatous trichiasis (TT) which abrade the corneal
surface of the eye, ultimately resulting in blindness [43].
It is currently estimated that 84 million individuals are
living with active disease, where the highest burden of
infection is concentrated in young children [42]. In
addition, 1.2 million people are estimated to be blind as
a result of infection [42]. While there has been some
success at controlling trachoma infection, it remains en-
demic in 50 countries.
The WHO aims to control infection and eliminate
trachoma as a public health problem by 2020 [43]. To
help achieve this, the WHO supports the implementa-
tion of the SAFE strategy: Surgery for trichiasis, Anti-
biotics for treatment, and Facial cleanliness and
Environmental improvements to reduce the probabil-
ity of transmission [43]. Effective control relies on the
successful implementation of antibiotic treatment as
well as long term reductions in the overall level of
transmission. The decision to declare that trachoma
has been controlled within a community or whether or
not further antibiotic treatment is required is based on the
prevalence of trachomatous inflammation–follicular (TF)
in children aged 1–9 years [43]. However, it is possible
that other surveillance data sources, such as trachomatous
inflammation-intense (TI) prevalence or the detection of
active chlamydial infection through PCR may provide
additional information on the dynamics of transmission
within the population [44]. This can help to assess
whether sustained control is being achieved or whether in-
fection is remerging.
Modelling approaches
Two distinct models were developed to address two key
areas in trachoma transmission control and surveillance.
The developed model by Gambhir and Pinsent [45] was a
deterministic susceptible, infected, susceptible (SIS) trans-
mission model, which was age-structured and followed indi-
viduals from their first infection to their last (a ‘ladder of
infection’), and accounted for the development of immunity
within the population as the number of infections experi-
enced increased. This model assessed the impact of multiple
annual rounds of MDA and the implementation of F and E
on the long-term transmission dynamics of infection, within
three different transmission settings. In addition, the short
and medium-term impact on the effective reproduction
number, Re, was also assessed within each transmission set-
ting, as a measure of the potential for post-treatment infec-
tion rebound.
Liu et al. based their model on a stochastic SIS process
[44]. The model was a hidden Markov process of infec-
tion at the community level, and numerical evaluation of
the Kolmogorov forward equations enabled straightfor-
ward likelihood fitting based on clinical trial data from
the Niger arm of the Partnership for the Rapid Elimin-
ation of Trachoma (PRET) study. Model fitting utilized
several observations, including PCR data, the clinical
sign TF, and the clinical sign TI. Because TF guides pol-
icy and intervention, we produced forecasts of future ob-
servations of TF, thereby evaluating model predictions
on a test set separate from the training set. Both TI and
laboratory infection tests led to moderate, but not sig-
nificant, improvement in forecasting the future level of
infection within the community and that including a
delay in TF recovery improves forecasting.
Policy implications
Gambhir et al. suggest that a combination of MDA and
reductions in the overall level of transmission within
both high and low transmission communities would en-
sure that long-term control of transmission could be
achieved (Fig. 5a). These control measures result in the
overall number of infections experienced by an individ-
ual in the community at any point in time becoming
lower than prior to the introduction of the interventions.
However, the rapid and dramatic reductions in transmis-
sion that may occur due to these interventions may re-
sult in a slower acquisition of immunity to infection.
This may mean that although individuals are getting in-
fected less frequently, when they do they have a higher
infectivity and are infectious for longer. To monitor
these potentially adverse outcomes it may be important
to collect infection samples from a sub-section of the
adult population, as well as young children to ensure
that reductions in population level immunity are not
occurring.
Liu et al. designed a model to assess which data
sources are more informative for predicting the future
state of infection in a community (Fig. 5b). They sug-
gested that TF data alone was just as informative for
forecasting the future level of infection in the commu-
nity as when TF, TI and PCR data were combined. If ap-
plied to data from particular settings, the model can be
used to determine which regions are likely to attain the
goals, and if not which additional interventions may be
necessary in order to achieve them. If regions are identi-
fied as requiring fewer resources than anticipated, these
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resources could be moved to areas less likely to attain
goals.
Knowledge gaps and next steps
A number of different model structures need to be com-
pared and statistically validated, to assess which is the
most suitable structure going forwards. For example, is
an SIS model without age structure sufficient to capture
the overall observed dynamics of infection? While indi-
viduals are no longer PCR positive, but are still TF posi-
tive, is it possible for them to become re-infected at this
point? High resolution data will also help to disentangle
the relationship and the time spent PCR and TF positive,
and help with the explicit modelling of both of these
stages. In addition, more longitudinal data will help to
assess trends in transmission over time that have oc-
curred as a result of different interventions. Much about
trachoma remains poorly understood, and will probably
remain unknown as we eradicate the disease. Models
need to be validated and calibrated in collaboration with
the International Trachoma Initiative (ITI) to make
more global projections on the feasibility of the 2020
goals and where additional resources may or may not be
needed. Yet for any model, an argument can be made
that something, possibly important, should be added to
it; validation through prediction can, in large part, re-
solve such issues - telling us whether our models are
adequate to guide elimination campaigns.
Intensified disease management diseases
A number of neglected tropical diseases are controlled
by increased diagnosis and management of cases (inten-
sified disease management, IDM). The four IDM dis-
eases in this study are Chagas disease, the Gambian
form of human African trypanosomiasis, leprosy globally
and visceral leishmaniasis on the Indian sub-continent.
Whilst these diseases cause significant morbidity and
mortality, the disease courses are quite long, the epi-
demic growth rate is slow and the transmission is usu-
ally highly focal. They are often associated with
disadvantaged populations and hard-to-reach groups.
Given this concentration of disease in populations with
poor access to care, and the potentially long time pe-
riods over which their disease course and dynamics
occur, these diseases have been difficult to study and so
quantitative estimates of key parameters are scarce. In
the model analyses of these diseases the authors have
aimed to provide novel estimates of key parameters and
provide both qualitative and quantitative insights on the
dynamics of these infections and their consequences for
control.
Chagas disease
Background
Chagas disease (etiological agent Trypanosoma cruzi) is
the most important zoonotic vector-borne disease in the
Americas, with an estimated 8 million people infected,
ten thousand deaths per year and a disease burden, as
Fig. 5 Schematic of trachoma results. The schematic includes results from: a) a transmission model including consideration of immunity by
Gambhir et al. [45]; and b) a statistical analysis of the most informative data for forecasting trends in prevalence by Liu et al. [44]
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estimated by Disability-Adjusted Life Years (DALYs), of
7.5 times that of malaria [46]. Chagas disease is endemic
in Latin America, and has been steadily spreading to
other parts of the world including North America,
Europe, and Australia [47]. Estimates suggest that over 8
million people are infected, but since many cases go un-
detected, the actual number of infections may be higher.
A study estimated the global annual burden to be $627 ·
46 million in healthcare costs and 806,170 DALYs [48].
However, since Chagas can result in chronic heart dis-
ease after years of being asymptomatic [46, 47], much of
the costs of Chagas disease occur years into the future.
Therefore, currently infected individuals are expected to
cost $7 · 19 billion per year and $188 · 80 billion through-
out their lifetimes [48]. Transmission mainly occurs via
the triatomine bug [47] (also known as the “kissing
bug”), which can acquire the T. cruzi parasite by taking a
blood meal from an infected mammal. Transmission
from vector to human occurs when a T. cruzi- infected
triatomine defecates (usually during or immediately after
taking a blood meal) on an uninfected human, deposit-
ing the parasite on the skin. The bitten person often fa-
cilitates the parasite entering the bloodstream by
rubbing or scratching the bite area and smearing the
bug faeces into the bite or other areas with ready access
to the bloodstream such as the eyes or mouth. Less fre-
quently, transmission can occur through blood transfu-
sion, congenital transmission (from infected mother to
fetus), and organ donation [47]. Transmission can also
occur orally through the ingestion of food contaminated
with infected triatomine bug faeces and laboratory acci-
dents [47]. Currently the main Chagas disease control
methods are triatomine bug control, protecting food
from contamination, and screening blood and organs for
T. cruzi. Vector control methods include insecticide
spraying, bed nets, and fixing the cracks in buildings
(e.g., improved housing). Vaccines and other medications
are under development [49–51].
The 2020 goals call for the interruption or reduction
of transmission across all routes, and an increase in the
number of patients under treatment. A major challenge
in achieving these goals is not what to do, but how to do
it on a wide enough scale to reach a sufficient propor-
tion of those infected or at risk. The two strategies for
interrupting vector-borne T. cruzi transmission are
spraying indoor residual insecticides (IRS) and housing
improvements. IRS must be applied on a regular basis to
avoid re-infestation, and this has led to insecticide resist-
ance in some triatomine species. Housing improvements
can be effective, but they are disruptive and expensive.
Thus, a central question is how often and for how long
must these strategies be carried out to eliminate trans-
mission, and which factors in the transmission scenario
affect these efforts?
Modelling approaches
The modelling approach of Peterson et al. [52] was to
examine the effect of synanthropic animals on T. cruzi
transmission and prevalence in humans, and how animal
presence affects the efficacy of vector control. Animals
are important to consider because in most Chagas-
endemic settings, there are numerous pets, livestock,
and vermin that not only serve as food sources for tria-
tomine bugs, but are also competent T. cruzi hosts. Thus
an important question is whether it is necessary to target
animals for Chagas control, as the current strategies only
target the vector.
Peterson et al. focused their efforts on using models to
test hypotheses on human-vector-animal interactions.
This qualitative analysis showed that it is likely that ani-
mals do amplify transmission to humans in the absence
of any vector control measures, because of their role as
additional food sources for the bugs leads to increases in
the vector population size (Fig. 6). However, if vector
control measures are carried out that prevent the vector
population from growing in the presence of animals,
then animals can have a beneficial effect, even without
reducing the vector population to zero, due to “diluting”
the bites of the remaining vectors. This effect is then in-
tensified if the animals are only food sources for the
bugs and not competent T. cruzi hosts, which is the case
for poultry or any other bird species.
Policy implications
These analyses highlight the importance of applying vec-
tor control to reduce total vector numbers, rather than
temporarily reducing vector biting on humans. In differ-
ent epidemiological settings, the most appropriate vector
control method may be different. In particular, the avail-
ability of alternative animal populations for food sources
which will enable the triatomine bugs to recover rapidly
following spraying, can undermine the control efforts.
These results also highlight the importance of entomo-
logical studies in endemic areas to understand the biting
patterns of the triatomine bugs and how these are af-
fected by changing densities of humans and other
animals.
Knowledge gaps and next steps
A number of substantial knowledge gaps still exist
regarding the transmission dynamics of Chagas disease,
its prevalence and incidence in many countries, the
potential points of intervention, the best ways to diag-
nose, monitor, and treat Chagas disease, and the impact
and value of different control measures. Modelling ef-
forts can help address these important gaps and guide
current and future data collection efforts and interven-
tion development and testing. An example of a subse-
quent modelling effort is to extend an initial model that
Hollingsworth et al. Parasites & Vectors  (2015) 8:630 Page 13 of 28
allowed an investigation of how animals impact the force
of infection. The researchers now plan to in parallel de-
velop the transmission models and to use other data to
inform the models on the force of infection by age and
the basic reproduction number, R0. An important source
of information on the dynamics of Chagas in different
areas will be age prevalence data from a variety of set-
tings. Some of these data are prior to any form of inter-
vention, which should allow estimation of the basic
reproductive number. The availability of both pre- and
post- intervention serologies will allow estimation of the
impact of control measures and the additional efforts re-
quired to break transmission to humans. By estimating
the force of infection for different regions and munici-
palities, researchers can examine the scale of the prob-
lem in a truly comparable way across Chagas-endemic
areas.
Human African trypanosomiasis, Gambian form
Background
Human African trypanosomiasis (HAT) is a parasitic
vector-borne disease spread by tsetse (Glossina spp) and
is fatal without treatment. There are two distinct forms,
Rhodesian and Gambian HAT, with the Gambian form
endemic in West and Central Africa and responsible for
almost all (>95 %) HAT cases. Efforts to control the dis-
ease have led to a large reduction in the burden of dis-
ease, with reported cases falling from around 38,000 in
1998 to less than 4000 in 2014 [53]. Consequently, it is
now targeted for elimination as a public health problem,
defined as less than 1 case per 10,000 people per year, in
90 % of endemic foci by 2020 [54]. There are two stages
of HAT disease and treatment is stage-specific.
Three main methods of intervention can be used in
HAT-endemic areas:
1. Those infected with HAT will usually seek treatment
by self-presentation at medical facilities when symp-
toms worsen, although this may not be until stage 2
disease.
2. Many endemic areas have active/mass screening
campaigns to detect and treat both stage 1 and 2
cases.
3. Vector control using tsetse targets has been shown
to substantially reduce tsetse population sizes [54].
However, vector control is not currently used in all
endemic areas.
Modelling approaches
In recent analyses, two research groups have independ-
ently addressed the feasibility of the WHO goal of elim-
ination as a public health problem by 2020 under
current strategies using mechanistic mathematical
models [55, 56]. Both models used differential equations
to quantify stage 1 and 2 disease in humans, tsetse infec-
tion and possible animal reservoirs (Fig. 7). Pandey et al.
also capture possible human population-level heterogen-
eity in exposure to tsetse bites and participation in
screening.
Fig. 6 Schematic of Chagas results. The schematic describes a new transmission model for Chagas disease used to analyse the consequences of
varying standard assumptions about the transmission cycle by Peterson et al. [52]
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The model of Pandey et al. was fitted to 2008–13
prevalence data from humans, non-human animals and
tsetse within the Boffa HAT focus in Guinea, where
mass screening and treatment have been combined with
vector control (Fig. 7b) [54]. Annual tsetse control using
tiny tsetse targets is modelled using a function which re-
flects a decline in their effectiveness throughout the year.
Fitting of the model to the trial data was used to esti-
mate key parameters on the underlying level of trans-
mission and the impact of vector control measures. The
calibrated model was used to estimate the achievability
of the 2020 goal under the scenarios of vector control
alone, or vector control combined with biennial or an-
nual screening under 2013 coverage levels. The model’s
projections accounted for the impact of the 2014–5
Ebola epidemic on HAT control efforts.
In a related approach, Rock et al. used data from
two health zones, Yasa-Bonga and Mosango, in
Bandundu province of the Democratic Republic of
Congo (DRC), one of the highest incident areas of
Gambian HAT (Fig. 7a). Bandundu has screening
campaigns, but, partly due to its size, has not yet im-
plemented a vector control programme. The model
was fitted to 13 years of case data to estimate the
underlying levels of transmission and the effectiveness
of current screening campaigns. The expected time to
elimination as a public health problem was predicted
for a range of hypotheses for human heterogeneity
under two levels of active screening: the highest level
achieved (in 2009); and the mean level observed
between 2000 and 2012.
Policy implications
Each modelling study included an analysis of the achiev-
ability of the 2020 goals in the setting analysed. Pandey
et al. predict that annual implementation of vector con-
trol, at the same level attained in 2013, has at least a
77 % probability of eliminating HAT as a public health
problem in Boffa by 2020. If biennial screening or an-
nual screening is conducted alongside vector control
then the probability of elimination by 2020 increases to
over 90 %.
While there is evidence that active screening and treat-
ment in Yasa-Bonga and Mosango have led to a 52–53 %
reduction in new infections over 15 years, Rock et al. pre-
dict that the region is unlikely to meet the elimination
goal until 2059–2091 under the highest level of current
active detection and treatment. Incorporating human het-
erogeneity in the model improves the fit to observed data;
the best model fit is obtained when humans who are more
exposed to tsetse bites are assumed to never participate in
active screening. Results suggest that current active
screening campaigns could be further improved by target-
ing high-risk individuals and those who have previously
not taken part in screening.
Knowledge gaps and next steps
Neither of these analyses were able to rule out the possi-
bility of an animal reservoir for infection due to the na-
ture of the available data. Pandey et al’s analysis suggests
that vector control is efficacious irrespective of a reser-
voir, but in the presence of a reservoir, intervention
strategies must be maintained, even after elimination, to
Fig. 7 Schematic of HAT results. The results include a) quantitative estimates of the level of heterogeneity in human exposure and screening
participation by Rock et al. [56]; and b) an assessment of strategies combining both human screening and tsetse control by Pandey et al. [55]
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prevent HAT re-emerging as a public health problem.
Future modelling work utilising data on trypanosome
prevalence in animals and tsetse host preference should
enable better determination of the role of animals in dis-
ease transmission.
The modelling results highlight the level of geographic
heterogeneity of HAT burden and the variety of inter-
vention strategies currently used. Whilst some areas,
such as Boffa, are on track to meet the 2020 goal, other
regions may need to strengthen their existing strategies
with complementary measures. In particular, Yasa-Bonga
and Mosango are hard-to-reach regions with high inci-
dence. Consequently, they are likely to be amongst the
hardest areas in which to achieve elimination.
Moving forward it will also be important to examine
how spatial heterogeneity in both transmission and in-
terventions at a local level may impact disease incidence
within a larger geographical area. To achieve this it will
be crucial to have good estimates of demography, popu-
lation sizes and, ideally, movements at a local level to in-
form models which include analyses of the spatial
distribution of cases.
Leprosy
Background
Leprosy, or Hansen’s disease, is an infectious disease
caused by the bacterium Mycobacterium leprae. Trans-
mission is believed to occur through close contact with
an infected person, but the route of transmission re-
mains largely undefined, and it would appear that only a
small proportion of people that are exposed will eventu-
ally develop the disease [57]. Leprosy is diagnosed based
on clinical signs and treated with multidrug therapy
(MDT). Leprosy control rests on early diagnosis and
treatment, which is thought to prevent both transmis-
sion and progression to leprosy-related disability.
Worldwide, more than 200,000 new leprosy cases are
detected and reported annually from 121 countries [58].
This number has been fairly stable in the past 8 years,
suggestive of ongoing transmission. Together, India,
Brazil and Indonesia account for 81 % of all new cases,
and only 13 countries reported more than 1000 new
cases in 2014. Recently, WHO has formulated ‘roadmap
targets’ for leprosy [3]. The targets set for the period
2015–2020, are: (1) global interruption of transmission
or elimination by 2020, and (2) reduction of grade-2 dis-
abilities in newly detected cases to below 1 per million
population at global level by 2020.
Modelling approaches
The three analyses in the collection use distinct modelling
and statistical approaches to assess progress of leprosy
control programmes in different settings. Blok et al. [59]
used a stochastic individual-based model SIMCOLEP to
assess the feasibility of achieving global elimination of
leprosy by 2020. SIMCOLEP simulates the life histor-
ies of individuals, the natural history of infection with
M. leprae, and the transmission of leprosy in a popula-
tion structured in households. Leprosy control in-
cludes passive detection and treatment. Household
members of a detected case can be subjected to con-
tact tracing. The model was fitted to the leprosy situ-
ation, including control, in India, Brazil and Indonesia
on national and sub-national levels using data from
the National Leprosy Elimination Program (India),
SINAN database (Brazil), and Netherlands Leprosy
Relief (Indonesia). Using the fitted model, future pro-
jections were made of the leprosy incidence, assuming
continuation of leprosy control programs.
Linear mixed-effects regression models were used by
Brook [60] to investigate the relationship between lep-
rosy case detection rate at the district level and several
state-level regressors: the incidence of tuberculosis, BCG
vaccination coverage, the fraction of cases exhibiting
grade 2 disability at diagnosis, the fraction of cases in
children, and the fraction of cases which were multiba-
cillary. Districts reported to have been targeted for en-
hanced case finding showed evidence of an increase in
case detection. However, substantial unexplained differ-
ences between districts were seen (both in terms of new
case detection rate and trend). Moreover, the overall rate
of decrease was very small, controlling for the enhanced
case finding.
Crump and Medley [61] developed a back-calculation
approach to investigate the infection dynamics of lep-
rosy. The model allows for varying effort or effectiveness
of diagnosis in different time periods. Publicly available
data from Thailand were used to demonstrate the results
that can be obtained as the incidence of diagnosed cases
falls [62]. Estimates of the incidence of new infections
and clinical cases were obtained by year, as well as esti-
mates of diagnostic efficacy. The method also provides
short-term forecasting of new case detection by disease
type, including disability status.
Policy implications
Blok et al. showed that although elimination at national
level is predicted by 2020, leprosy will still remain a
problem at sub-national level (Fig. 8a). These high-
endemic regions have multi-million populations in
which rapid progress of leprosy control, even if con-
ducted optimally, will not be achieved soon. The au-
thors conclude that ongoing transmission of M. leprae
will make global elimination of leprosy unlikely by
2020. Further control measures are needed to achieve
the goals [59].
The analysis of new case detection rates from India by
Brook et al. suggests an endemic disease in very slow
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decline, with heterogeneity across state and district
levels (Fig. 8b). Active case finding was associated with a
higher case detection rate, but not rapid leprosy control.
Finer geographic resolution would improve analysis and
bolster evidence-based policy assessment. Objective sur-
veys may have a role to play in leprosy program evalu-
ation, in view of differences in case reporting and in
active case finding efforts.
Crump and Medley found that Bayesian back-
calculation shows great potential to provide estimates of
numbers of individuals in health/infection states that are
as yet undiagnosed (Fig. 8c). This has the potential to
provide valuable information for those managing or
evaluating control programmes. The methodology is
driven by available data, and provides an impetus for
better reporting in that results can be quickly fed back
to programs.
Knowledge gaps and next steps
There is relatively little known about leprosy with any
degree of certainty. The long delay between infection
and disease means that current diagnoses are a poor
measure of current infection. Further modelling work
may help to address this and also highlight areas where
data collection would be valuable.
Blok et al. plan to include grade 2 disabilities and con-
sider intervention programmes targeting contacts of leprosy
patients; such as chemoprophylaxis, immunoprophylaxis
and an anticipated diagnostic test for sub-clinical cases.
Brook et al. plan to use their statistical modelling to inform
a stochastic model to explore the use of targeted surveys
and the effect of sustained active case detection. The back-
calculation model of Crump and Medley will be further de-
veloped to consider gender and age. The three groups will
be working with national and regional data of variable
endemicity.
Visceral Leishmaniasis
Background
Visceral leishmaniasis (VL) is caused by chronic infec-
tion with protozoan Leishmania parasites and is spread
by infected sandflies. Annually, more than 80 % of the
200,000–400,000 global cases of symptomatic disease,
and an estimated 15,000–30,000 deaths occur on the
Indian sub-continent (ISC) [63]. There, VL is caused by
Leishmania donovani, is spread by a single sandfly spe-
cies, Phlebotomus argentipes, and is considered to be
solely anthroponotic. VL, also known as kala-azar (KA),
has been targeted by the WHO for elimination as a pub-
lic health problem on the ISC, defined as less than 1
new case per 10,000 people per year at sub-district level,
by 2017. Existing interventions focus on reducing trans-
mission, mainly by reducing vector population densities
through indoor residual spraying (IRS) with long-lasting
insecticides (DDT and synthetic pyrethroids) and prompt
diagnosis and treatment.
Individuals that develop KA, show symptoms of pro-
longed fever, anaemia, weight loss and spleen and liver
enlargement, and usually die without treatment. Most
individuals recover following successful treatment,
though a small proportion (2–10 % on the ISC) go on to
develop post-kala-azar dermal leishmaniasis (PKDL), a
non-fatal dermatological condition characterised by a
nodular or papular skin rash. However, the majority of
individuals infected with the parasite are asymptomatic,
but may be infected for many years; it is unclear if indi-
viduals ever completely lose infection and how long
immunity lasts for those who develop it.
Modelling approaches
To address the question of whether the 2017 VL elimin-
ation target can be met with current interventions, it is ne-
cessary to obtain robust estimates of key epidemiological
Fig. 8 Schematic of leprosy results. The results include: a) a transmission model fitted to national and regional data from India, Brazil and Indonesia to
predict future trends in leprosy incidence by Blok et al. [59]; b) statistical modelling of regional case detection data from India by Brook et al. [60]; and
c) a back-calculation method to investigate underlying infection dynamics and predict future incidence by Crump and Medley [61]
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parameters and to assess how uncertainties in transmission
affect the efficacy of different interventions. These issues
have been tackled in separate analyses by two research
teams [64, 65].
Chapman et al. [65] used statistical analyses to assess
the risk of progression to KA based on serology test re-
sults, and a probabilistic model to estimate key parame-
ters in the natural history of VL. Their model is fitted to
data from a detailed epidemiological study conducted in
three highly endemic villages in Bangladesh between
2002 and 2004, at which time no control interventions
other than antimonial treatment and untreated bed net
use were in place in the region. By fitting to the annual
serology (rK39 antibody and leishmanin skin test) test
results and KA onset and treatment dates from the
study, the researchers estimate the duration of asymp-
tomatic infection, the duration of immunity and the
proportion of asymptomatic individuals that progress
to KA.
Le Rutte et al. [66] describe the quantification of VL
transmission between humans and sandflies on the ISC
with 3 deterministic age-structured models. The princi-
pal source of infection to sandflies remains unknown,
and Le Rutte et al. test three hypotheses for the source
in their models - namely (1) asymptomatic infections,
(2) re-activation of infection after recovery from initial
infection, or (3) PKDL. All 3 models are parameterised
with age-structured data from the KalaNet study, which
consists of annual prevalence of infection (PCR), detect-
able immune responses (DAT) and incidence of VL in
highly endemic clusters in India and Nepal as well as the
percentage prevalence of infected sandflies in Nepal.
The inclusion of age-structure in the models allows for
detailed fitting and age-related heterogeneity in sandfly
exposure. With these models they predict the impact of
current interventions on VL incidence to estimate the
feasibility of achieving the 2017 elimination target for
the ISC. Predictions are made for three levels of VL en-
demicity and for optimal and sub-optimal IRS effective-
ness, which may vary due to quality of implementation
and vector resistance to DDT.
Policy implications
The statistical analyses by Chapman et al. show that in-
dividuals who initially have high antibody levels are
more likely to progress to KA than individuals with low
or moderate antibody levels, and that those who sero-
convert to high antibody levels have an even higher
chance of developing KA (Fig. 9a). These findings sug-
gest that individuals at high risk of progressing could be
identified by screening, so that their infectious period
and onward transmission could be reduced with im-
proved access to treatment and targeted IRS. The fitting
of the probabilistic model to the data gave estimates of
147 days (95 % CI 130–166 days) for the average dur-
ation of asymptomatic infection and 14.7 % (95 % CI
12.6–20.0 %) for the proportion of asymptomatic indi-
viduals progressing to KA - much longer and higher es-
timates than those reported previously [66], suggesting
that asymptomatic individuals may contribute signifi-
cantly to transmission.
The models of Le Rutte et al. show that the predicted
impact of IRS differs per model variant, depending on
whether asymptomatics, re-activated infections or PKDL
cases constitute the main reservoir of infection (Fig. 9b).
Further, the feasibility of achieving elimination of VL on
the ISC strongly depends on pre-IRS endemicity and the
effectiveness of IRS itself. Based on the assumption that
Fig. 9 Schematic of VL results. The results include: a) new estimates of epidemiological parameters by Chapman et al. [64]; and b). a qualitative
investigation of the impact of different life history assumptions on transmission dynamics and intervention efficacy by Le Rutte et al. [65]
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cases of asymptomatic infection are the main reservoir
(due to high numbers, and despite low infectivity to-
wards the sandfly) and IRS is implemented optimally,
the authors predict that VL may be eliminated in low
and moderately endemic areas within six years of the
start of IRS. For highly endemic areas and areas with
sub-optimal IRS, additional interventions may be
required.
Knowledge gaps and next steps
The relative infectivity of individuals in different dis-
ease stages is currently not known and thus neither is
their contribution to transmission. Ongoing xenodiag-
nostic studies and additional longitudinal data on the
prevalence of infection in sandflies during interventions
will inform the transmission models regarding the most
likely reservoir of infection, and enable the implemen-
tation of an appropriate model structure in an
individual-based model by Le Rutte et al. In regions
where it is predicted that the target of <1 VL case per
10,000 capita will not be reached, additional interven-
tions may be required; the impact of these (such as a
potential vaccine) will be explored by Le Rutte et al.
To aid estimation of the relative contributions of dif-
ferent disease groups to transmission, spatial and tem-
poral variation in VL risk will be included in the
probabilistic model of Chapman et al. Fitting this model
to other longitudinal datasets will provide more robust
estimates of the different disease stage durations and
proportion of individuals progressing to disease, and an
indication of the extent to which these parameters de-
pend on endemicity and other risk factors. This work
will be used to inform the development of future trans-
mission models of VL for assessing the efficacy of differ-
ent interventions.
Discussion
The publications in this collection bring together a var-
iety of different approaches to provide novel quantitative
analyses that can inform policy development on the con-
trol and elimination of nine NTDs. For the PCT diseases
existing and novel models have been brought together to
assess the impact of current strategies, identify areas
where they need to be adjusted and provide consensus
insights on likely coverage needs and program duration
(Table 2). For the IDM diseases, new models and
methods have been developed and key parameters (such
as the incubation period or proportion of infections
accessing care) have been estimated (Table 3). In both
areas, these are important steps forward. These analyses
also identify the need for further work, as well as more
rigorous model comparison and testing against more ex-
tensive datasets. Across the diseases, there are a number
of common themes that emerge:
The importance of epidemiological settings
As expected, the details of an epidemiological setting, in
terms of baseline prevalence, heterogeneities in risk by
age and across the population and in terms of program
implementation, are crucial in determining program suc-
cess. The analyses of the PCT helminthiases in particular
highlight that, in areas with different transmission rates,
even with the same helminth (and vector), very different
combinations of interventions are required to achieve
control or elimination. As these models are developed
further and linked more closely with programmatic ac-
tivities, there are opportunities to better develop inter-
ventions aligned to local conditions.
The importance of epidemiological setting means that
because these diseases are spatially heterogeneous, sam-
pling for the impact of control is non-trivial, and low re-
gional levels of infection may not be indicative of low
transmission across an area (as illustrated by sub-
national data for leprosy). A spatially heterogeneous
transmission landscape (as is the case for NTDs) com-
bined with some level of inevitable heterogeneity in how
interventions are delivered and received is likely to lead
to further heterogeneities in the levels of transmission
following years of interventions. This may result in ‘hot-
spots’ where additional interventions are required,. Al-
though it may be difficult to identify or predict all hot
spots, the modelling can demonstrate how the presence
of hot spots contributes to heterogeneity and the need
to adapt responses when such a location is detected.
Heterogeneities in risk and heterogeneities in access to care
A number of the analyses in this collection include
models of both heterogeneities in risk of exposure and,
importantly, access to care. Heterogeneities in transmis-
sion risk are more easily identified for helminth infec-
tions due to heterogeneities in pathogen load. For
vector-borne infections there is also the possibility of
measuring heterogeneities in exposure to insect bites. As
demonstrated for helminth infections, two settings with
similar prevalence but with very different levels of het-
erogeneity in risk may require quite different levels of
interventions. In addition to these biological variations,
particular behaviours can increase risk, whether it is
children having higher exposure to STH, or adult males
possibly having higher exposure to HAT. These will lead
to differential impact of the available interventions.
These analyses have also highlighted that where high-
risk groups are additionally less able to access care, or
where there are other semi (or fully) systematic biases in
access to interventions, this can have a large impact on
the success of a programme. When the coverage rate is
assumed to randomly reach any person with equal
chance, the interpretation can conceal the fraction of a
population that systematically misses the intervention.
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Table 2 Summary of modelling techniques used, PCT diseases
Paper Model Fitted to data
from:
Predictions
tested?
Technical advances Model accounts for Next steps
Vector/environment
dynamics
Heterogeneity in risk Access to interventions
Lymphatic filariasis
Irvine et al. Stochastic
individual
Kenya and Sri
Lanka
Yes Heterogeneity in transmission
and extinction dynamics
greatly affects time to
elimination
Deterministic
vector dynamics.
Single pool of
vectors
Gamma distributed
risk in exposure
Spectrum of access to
repeat rounds of MDA
and vector control, with
cross-correlations with
risk
Fit the model to
intervention data and
understand transmission
dynamics at low
densities
Jambulingam et
al.
Stochastic
individual
35 villages in
India.
Yes Association between
antigenaemia and presence of
adult worms.
Deterministic
vector dynamics.
single pool of
vectors
Age dependent,
gamma distributed
exposure
Individual’s treatment
compliance is semi-
systematic
Estimating vector
infection thresholds.
Estimating probability of
elimination
Singh et al. Deterministic Data from 22
villages from
Africa, South
East Asia, and
Papua New
Guine
No Bayesian fitting including
information about model
inputs and outputs
Deterministic
vector dynamics.
single pool of
vectors
Negative binomial
distribution of
worms
Random Estimating thresholds for
true elimination. Further
understanding of
parameter uncertainty
Onchocerciasis
Stolk
et al.
ONCHOSIM Stochastic Cameroon Yes Bringing the two models
together and understanding
differences in predictions
Deterministic
vector dynamics.
Single pool of
vectors
Age dependent,
gamma distributed
risk
Age-dependent
probability of receiving
treatment. Lifelong
compliance factor
The two models give
different Mf intensities
and prevalences after
MDA, which needs to
be investigated further
EPIONCHO Deterministic Cameroon Yes Single vector
compartment
Age- and sex-
specific exposure to
blackfly
Compliant and non-
compliant groups
Schistosomiasis
Anderson et al. Deterministic Kenya Yes Using an age-structured model
to assess the feasibility of elim-
ination, and comparing model
predictions to reinfection data
Environmental
reservoir, constant
decay rate. No
explicit
consideration of
snail dynamics
Variability in
exposure as a
function of age.
Negative binomial
distribution of
worms
Treatment reduced
worms by a given
fraction in a given
proportion of individuals,
equivalent to random
treatment
Better modelling of
transmission by age,
immunity, worm mating.
Stochastic model
Gurarie et al. Deterministic Kenya Yes Investigating MDA success in
different scenarios using a
modelling framework
Snail transmission
compartments
None A fraction of adult worms
are killed by each
treatment
Consideration of snail
dynamics.
Soil-transmitted helminthiasis
Coffeng et al.
(hookworm only)
Stochastic,,
individual
Vietnam Yes Developed WORMSIM, a new
generalised framework for
modelling transmission and
control of helminths
Environmental
reservoir
Gamma distributed
total egg output,
two scenarios: high
or low variation in
host susceptibility
Participation is either
random, fully systematic
or a mix.
Lifespan of eggs in the
environment, MDA
coverage over different
age groups
Truscott et al. Deterministic
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Table 2 Summary of modelling techniques used, PCT diseases (Continued)
India (Ascaris),
St Lucia
(Trichuris) and
Zimbabwe
(hookworm)
Yes (Ascaris
only)
Fitting against multiple
treatment rounds data
Pool of
environmental
infective material,
exponential decay
Negative binomial
distribution of
worms in individuals
All individuals have a
probability of receiving
treatment
Understanding spatial
and age heterogeneity,
systematic non-
compliance
Trachoma
Gambhir et al. Deterministic Tanzania and
Gambia
No Including MDA interventions
into the modelling framework
None None A subset of the infected
group are moved to the
susceptible compartment
Validating against
multiple datasets, better
modelling of immunity
Liu et al. Stochastic
compartmental
Niger No Constructing a stochastic
transmission model including
different ways of modelling
each observation by fitting to
TF only or to TF, TI and PCR
None None All individuals have a
probability of receiving
treatment
Further fitting to
intervention data.
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Table 3 Summary of modelling techniques used, IDM diseases
Paper Model Fitted to
data from:
Predictions
tested?
Technical advances Model accounts for Next steps
Vector/environment
dynamics
Heterogeneity in risk Access to interventions
Chagas disease
Peterson
et al.
Deterministic Parameter
values
were set
according
to the
literature
No Formulating a transmission
model and analysing the
consequences of varying
standard assumptions on the
transmission cycle
Deterministic
vector dynamics
with animal hosts
in some modelling
scenarios
None Not applicable - vector control only Develop two
independent
transmission models.
Estimation of
changes in
transmission rates
Human African trypanosomiasis, Gambian form
Pandey et
al.
Deterministic Boffa,
Guinea
Yes Data cannot identify whether
there is an animal reservoir. But
in the presence of animal
reservoir, there is high risk of re-
emergence of HAT as public
health problem.
Includes tsetse and
animal
compartments
None All individuals have a probability of
receiving treatment
Evaluating 2020 goal
in other foci and
impact of
heterogeneity in
human exposure to
tsetse.
Rock et al. Deterministic Bandundu,
DRC
No Data supports the existence of
an unscreened, high-risk popu-
lation, but cannot identify
whether there is an animal
reservoir
Includes tsetse and
animal
compartments
High risk and low risk
human compartments
Randomly participating and non-
participating human compartments
Projecting impact of
vector control in DRC
Leprosy
Blok et al. Stochastic
individual
India, Brazil
and
Indonesia
Yes Applied SIMCOLEP to predict
future leprosy incidence in
India, Brazil and Indonesia
Not applicable Susceptibility: 20 % of
population is susceptible;
Type of leprosy: MB vs PB;
Contact structure: general
population vs within
households
All individuals that have been
diagnosed with leprosy receive MDT
treatment. Probability of being
diagnosed is determined by passive
case detection delays and possible
active case finding activities.
Assess which
additional
interventions are
needed to meet the
goals
Brook et
al.
Statistical 604
analytic
districts in
India
No Enhanced active case finding
was associated with a higher
case detection rate
Not applicable Not applicable Not applicable Develop
independent
stochastic
compartmental
transmission model
Crump &
Medley
Statistical Thailand Yes Back-calculation can estimate
the number of undiagnosed
cases from diagnosed incidence
rates
Not applicable Not applicable Not applicable Consideration of
gender and age.
Analysis of other
countries.
Visceral leishmaniasis in the Indian sub-continent
Chapman
et al.
Statistical Bangladesh No Estimating durations of
asymptomatic and symptomatic
infection
Not applicable Proportional hazards
model for different risk
factors including age, sex
and bed net use
Not applicable Developing a
transmission model.
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Table 3 Summary of modelling techniques used, IDM diseases (Continued)
Le Rutte
et al.
Deterministic India and
Nepal
(KalaNet)
Yes Developed three model
structures, each with a different
reservoir of infection, all fitting
the data.
Vector population,
deterministic.
Age-dependent sandfly
exposure.
All individuals have a probability of
receiving diagnosis, treatment, and
vector control (IRS).
Implement best
model structure in
stochastic individual
based model. Explore
effect of additional
interventions.Added heterogeneity in sandfly
exposure.
Applied models to predict
future VL incidence with
current interventions.
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Models that include systematic factors in coverage are
useful for relating to the practical realities of implemen-
tation, and thus help inspire operational improvements
that reach the specific subpopulations previously at high
risk for infection.
Modellers can characterise these heterogeneities in
some settings, but of course not for all settings at all
times. Given limited data, the modellers have been able
to estimate some of the parameters that govern this vari-
ation in these settings, and have presented the sensitivity
of their results to these underlying parameters.
Challenges of elimination as a public health problem versus
“true” elimination
The first formal definitions of the public health targets
for infectious disease were defined at a multi-
disciplinary conference [67]. Since then the definitions
have become somewhat corrupted: what is now com-
monly termed as “elimination” or “elimination as a pub-
lic health problem” is more formally defined as control:
“Reduction of disease incidence, prevalence, morbidity
or mortality to a locally acceptable level as a result of de-
liberate efforts. Continued intervention measures are re-
quired to maintain the reduction”. The reason for the
slippage in terminology is, as recognised at the conference,
that political motivation to achieve elimination has to be
developed and maintained. The current situation is poten-
tially dangerous: most of the targeted NTDs are ap-
proaching “elimination”, but the models indicate that
continued intervention is required to remain at the levels
reached. The experience with leprosy indicates [68] that if
achieving “elimination” results in a reduction in control
efforts, at best progress is stalled and at worst disease will
rebound. We need now to consider redefining the targets
to be closer to true elimination: “Reduction to zero of the
incidence of infection caused by a specified agent in a de-
fined geographical area as a result of deliberate efforts.
Continued measures to prevent re-establishment of trans-
mission are required.” Modelling can help define these
new targets.
Next steps
Testing model predictions and model comparison
One of the strengths of this research project is the scien-
tific robustness that comes from having independent
modelling groups using different methods to address the
same problems and the opportunities for testing predic-
tions from multiple models. This has been most notably
for HIV and malaria [69, 70] and there are lessons to be
learned from the successes of these projects. For NTDs
there has been some, limited, testing of model pre-
dictions against epidemiologic or programmatic data
(Tables 2 and 3). This needs to be extended quite
considerably in the next phase of this research
project. By providing data from initial time points
and asking the modellers to predict later time
points, we will gain a better understanding of how
the data informs parameter estimation and of par-
ticular weaknesses or strengths in the models. This
will improve confidence in the model outputs.
Given the independent approaches within this research
project and in the wider NTD modelling community, it
is necessary to bring these results together and provide
consensus information, whether through informal sum-
maries (presented here), or through more rigorous
methods. Possible approaches to arriving at consensus
answers to the consortium’s research questions include:
1) analysis of the individual model projections,
discussion on the differences and the possible causes
of those differences and agreement on the most
likely projection through discussion: Model
comparison
2) arriving at a consensus model, through discussion
on the strengths and weaknesses of each group’s
approach for given geographical locales. This model
will then be refitted to the baseline data and
projected forward: Consensus Model building
3) mathematically combining the forecasts of each
model through e.g., averaging. The cone of
uncertainty for the forecasts is delineated by the
upper and lower forecasts of each group. This is the
approach of the international panel on climate
change’s (IPCC) global surface temperature
projections: Ensemble Forecasting
Each of these approaches has positives and negatives,
which require further discussion. The joint onchocercia-
sis paper in this collection has brought together two
modelling approaches which have been used for many
years, and is gradually developing an understanding of
what particular aspects of these models have generated
different estimates of the number of rounds of MDA re-
quired to achieve particular targets [71]. This is a
process of investigation, and through future model test-
ing against multiple-timepoint programmatic data, a fur-
ther quantitative assessment of the appropriate sets of
assumptions and parameter sets can be made.
The development of a consensus model may be seen
as a desirable aim from some stakeholders who would
like a single answer to policy questions for very sound,
practical reasons. However, built into this project is the
recognition of the fact that different model assumptions
and choices on how they are implemented can give dif-
ferent results and by using these different approaches we
improve the scientific robustness of our conclusions. In-
deed, arguably, for the diseases for which there has been
very little previous modelling, independent analysis of
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the very few datasets which are available has led to a
greater range of model assumptions than joint working
would have generated, which builds more scientific
robustness.
Ensemble forecasting, bringing together different
models and weighting their output, is the current state-
of-the-art in climate forecasting, and has been done to
some extent in epidemiological modelling, but the
weighting of the different models is challenging.
In the short term we hope to progress in our under-
standing of the different outputs of these models
through carefully managed model comparison in order
to provide consensus guidance on the key policy
questions.
Data
As with all epidemiological modelling, there is a need
for the models to be informed by high quality clinical
and epidemiological data. The research and implementa-
tion community has been very supportive of this work
so far, and there will be a greater number of re-analyses
of old data, as well as analyses of new data, in the future.
Part of our role is to improve access to these data for
other modellers both now and in the future. We are cur-
rently collating a catalogue of the data that is used in
our studies, and aim to facilitate access to these data for
other modelling groups. It is important to remember
that there are limited datasets currently available for
modelling NTDs, and we should not be complacent that
if we have modelled the few datasets available that we
have a full understanding of the dynamics of these dis-
eases. In particular, the models are very poor at replicat-
ing the behaviour of systems at low prevalence due to
the high variability in potential outcomes. This will be a
particular challenge for the future.
Model-informed data collection is a desirable outcome
of this work, as it will broaden our understanding of the
epidemiology [72, 73] and improve control. Some groups
are actively seeking out such studies or are involved in
the design of studies with these goals in mind, such as
the Tumikia study in Kenya [74], which investigates the
possibility of interrupting STH transmission though
MDA. There are a number of similar activities across
the nine NTDs.
The interpretation of raw data is sometimes hampered
by issues with current diagnostic techniques. For ex-
ample, models of helminth transmission are usually
based around representations of worm numbers within
hosts, but the connection between worm burdens and
the output of egg-counting diagnostic techniques, such
as Kato-Katz, or microfilarial counts are not well charac-
terised, although it is known that sensitivities can be
quite low. Newer diagnostics may provide more sensitive
methods, but the quantification of load may be lost. It is
therefore essential that the models are informed by the
individual-level data on the relationship between differ-
ent diagnostics, as well as tested against population-level
intervention data using these diagnostics, not only to
data using older methods. Any clinical or field trial of a
diagnostic is an opportunity to work with the study de-
signers to ensure that key variables are collected measur-
ing model parameters linking the detection characteristics
to immunology and with multiple diagnostic methods.
The additional study data may come at no added cost or
additional funds may be required for collaboration on a
broadened scope. Timing is critical as many of the NTDs
drop in incidence and research focus may shift elsewhere.
At the same time data are more critical to providing a use-
ful degree of certainty in the projections of low transmis-
sion levels.
For the IDM diseases, diagnostics are often poor at
identifying active infection, and interpreting case data
requires an understanding of the underlyling ‘effort’ in
detecting cases. For these diseases it is important that
analyses of such data are informed through close discus-
sions with those who collected or collated the data. The
quantification of underlying trends in incidence from
case data requires a good understanding of the incuba-
tion period and the likely pathway from onset of illness
to care, and how this varies by setting an by, for ex-
ample, age, sex and socio-economic setting. It may be
that this will never be quantifiable, and therefore inde-
pendent measures of exposure, such as serological sur-
veys, will be needed to assess program success and,
importantly, evaluate local elimination.
Practical utility of models for research and public health
community
For many of the papers we have released the code
underlying the models. The remaining groups have also
committed to releasing their code within the next
months. The aim is to release the models in a format
that expert epidemiological modellers can use now and
in the future. This is to ensure that the work presented
here is repeatable science, and that others can build on
the work initiated here.
There is an admirable increasing trend for epidemio-
logical model code to be realised and this generates some
interesting points of discussion. Many of the models have
been built for the analyses published in the collection and
are subject to continuing development. They are already
being altered to incorporate new intervention tools as they
emerge such as the triple drug for lymphatic filariasis and
oral stage-independent drugs for HAT, in order to simu-
late possible impact before they are rolled out.
Publishing the model code increases our collective re-
sponsibility to foster the acquisition of technical skills
for anyone seeking to learn to use them [75]. The
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configuration of the models and the preparation of input
data require knowledge of internal model structure and
a large amount of statistical data processing if the model
is to be adapted to any specific setting. Simply making
educational resources known can efficiently guide new
model users to the appropriate classes, lectures, litera-
ture, etc. We hope that the release of these models will
stimulate opportunities for more collaborations and
knowledge sharing, particularly with researchers in en-
demic countries. The value of the time invested in the
formal and informal collaborations that will arise from
them must be regarded as precious.
Of course, any model can be inadvertently misused giv-
ing misleading outputs and, as they have been released in
its current form they need expert use. The original devel-
opers of the models currently lack the capacity for tech-
nical support ordinarily provided by a commercial
software company, and the code should not be viewed as
being produced for that level of use. The question still re-
mains whether these models should be made available for
local policy decision by development of more user-
friendly interfaces, and also whether modelling expertise is
required at that level [75]. For the moment, most of these
models are not yet sufficiently validated to provide that
local level of precise policy development, but through in-
creased model testing and comparison that may become
possible in future, provided they are sufficiently informed
by, and tested against, the right data.
Conclusion
This collection of research papers represents an important
step forward for the evidence base for control and elimin-
ation of NTDs. They highlight settings where the 2020
goals, and even true elimination, are likely to be achieved
using the current strategies. They also indicate that there
are likely to be additional combinations of interventions re-
quired in other settings. These results do not provide the
evidence for dramatic changes in policy, but can guide
thinking and provide indications of ways forward which
can be tested in future studies and analyses. The overarch-
ing messages of the models are highlight the importance of
 heterogeneity in risk of infection (and reinfection)
and identifying which groups may maintain
transmission as overall levels are reduced.
 heterogeneity in access to and acceptability of
interventions, and possible systematic or semi-
systematic patterns in any lack of coverage.
 considering transmission rates when considering
strategies and endpoints
 clarity on the end goal of these programs and the
development of strategies to maintain the gains
achieved through elimination as a public health
problem.
Through continuing collaboration across this team of
modellers and their partners these researchers aim to
provide further quantitative analyses which will assist
the global effort to reduce the burden of NTDs towards
the 2020 goals and beyond.
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